Best ejection fraction using Metoprolol as pretreatment in acute myocardial infarction

Original title: Long-Term Benefict of Early Pre-Reperfusion Metoprolol Administraction in Patients With Acute Myocardial Infaction. From the METOCARD-CNIC Trial. Reference: Gonzalo Pizarro et, al. J Am Coll Cardiol 20141;63:2356-62

 

The anterior infarction with ST- segment elevation has a high morbidity and mortality, both in the acute phase as well as after the presence of heart failure, arrhythmias or sudden death. Multiple strategies have been employed to reduce these risks. 

This study analyzed 202 patients admitted experiencing an anterior infarction with ST segment elevation within the first 6 hours of the onset of symptoms and a Killip class ≤ 2. We excluded those who had a blood pressure

Conclusion: 

In patients with anterior infarction undergoing primary angioplasty, Metoprolol pretreatment resulted in improved ejection fraction at follow-up, less deterioration of systolic function, reduced need for cardio defibrillators and less re-hospitalization for heart failure. 

Comment 

This study shows that in the context of previous anterior infarction within six hours and without hemodynamic compromise, a simple and inexpensive strategy favors the evolution improving ventricular function and reducing hospitalizations and costs in health systems. 

Courtesy Dr Carlos Fava
Interventional cardiologist
Favaloro Foundation
Buenos Aires 

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...